Answer
Lutetium (177Lu) vipivotide tetraxetan (Pluvicto) binds with high affinity to PSMA on prostate cancer cells, allowing lutetium-177 beta-minus emissions to deliver radiation to targeted and surrounding cells, causing DNA damage that can lead to cell death.
Sources for this answer
- Pluvicto 1,000 MBq/mL solution for injection/infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 7Document updated
Sources checked